 |
 |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
3 December 2002 | Volume 137 Issue 11 | Pages 917-929
Background: In U.S. men, prostate cancer is the most common noncutaneous cancer and the second leading cause of cancer death. Screening for prostate cancer is controversial.
Purpose: To examine for the U.S. Preventive Services Task Force the evidence of benefits and harms of screening and earlier treatment.
Data Sources: MEDLINE and the Cochrane Library, experts, and bibliographies of reviews.
Study Selection: Researchers developed eight questions representing a logical chain between screening and reduced mortality, along with eligibility criteria for admissible evidence for each question. Admissible evidence was obtained by searching the data sources.
Data Extraction: Two reviewers abstracted relevant information using standardized abstraction forms and graded article quality according to Task Force criteria.
Data Synthesis: No conclusive direct evidence shows that screening reduces prostate cancer mortality. Some screening tests can detect prostate cancer at an earlier stage than clinical detection. One study provides good evidence that radical prostatectomy reduces disease-specific mortality for men with localized prostate cancer detected clinically. No study has examined the additional benefit of earlier treatment after detection by screening. Men with a life expectancy of fewer than 10 years are unlikely to benefit from screening even under favorable assumptions. Each treatment is associated with several well-documented potential harms.
Conclusions: Although potential harms of screening for prostate cancer can be established, the presence or magnitude of potential benefits cannot. Therefore, the net benefit of screening cannot be determined.
Author and Article Information
From University of North Carolina at Chapel Hill, Chapel Hill, and Research Triangle Institute, Research Triangle Park, North Carolina.
Disclaimer: The authors of this article are responsible for its contents, including any clinical or treatment recommendations. No statement in this article should be construed as an official position of the U.S. Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.
Acknowledgments: The authors acknowledge the continuing support of David Atkins, MD, MPH, and the guidance and feedback of Cynthia D. Mulrow, MD, MPH, University of Texas at San Antonio, Paul S. Frame, MD, Cohocton, New York, and other members of the USPSTF. They thank the staff of the Research Triangle Institute–University of North Carolina Evidence-based Practice Center, including Audrina J. Bunton, BA, Linda Lux, MPA, and Sonya Sutton, BSPH, for substantive and editorial work and Loraine Monroe for secretarial assistance. They also thank Rainer Beck, MD, Paul Godley, MD, MPH, and Kenneth Fink, MD, MPH, for assistance in reviewing articles. In addition, they thank the staff from the University of North Carolina at Chapel Hill and the Cecil G. Sheps Center for Health Services Research, including Timothy S. Carey, MD, MPH, Anne Jackman, MSW, Lynn Whitener, MSLS, DrPH, and Carol Krasnov. They also thank the peer reviewers of the complete systematic evidence review: Michael Barry, MD, Medical Practices Evaluation Center, Boston, Massachusetts; John W. Feightner, MD, MSC, Canadian Task Force on Preventive Health Care, London, Ontario, Canada; Theodore Ganiats, MD, University of California at San Diego, La Jolla, California; Marc B. Garnick, MD, Beth Israel Deaconess Medical Center, Boston, Massachusetts; Richard Hoffman, MD, MPH, Albuquerque Veterans Affairs Medical Center, Albuquerque, New Mexico; Barnett Kramer, MD, National Institutes of Health, Bethesda, Maryland; David Lush, MD, Medical College of Pennsylvania, Philadelphia, Pennsylvania; Curtis Mettlin, MD, Roswell Park Cancer Institute, Buffalo, New York; and Ian M. Thompson Jr., MD, University of Texas Health Sciences Center at San Antonio, San Antonio, Texas.
Grant Support: This study was conducted by the Research Triangle Institute–University of North Carolina Evidence-based Practice Center under contract to the Agency for Healthcare Research and Quality, Rockville, Maryland (contract no. 290-97-0011, task order 3).
Requests for Single Reprints: Reprints are available from the Agency for Healthcare Research and Quality Web site (http://www.ahrq.gov/clinic/uspstffix.htm) or the Agency for Healthcare Research and Quality Publications Clearinghouse.
Current Author Addresses: Dr. Harris: Cecil G. Sheps Center for Health Services Research, CB# 7590, University of North Carolina School of Medicine, 725 Airport Road, Chapel Hill, NC 27599-7590.
Dr. Lohr: Research Triangle Institute, PO Box 12194, 3040 Cornwallis Road, Research Triangle Park, NC 27709-2194. CLINICAL GUIDELINES
Screening for Prostate Cancer: An Update of the Evidence for the U.S. Preventive Services Task Force
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  H. Dixon, M. Scully, M. Wakefield, and M. Murphy The prostate cancer screening debate: public reaction to medical controversy in the media Public Understanding of Science, January 1, 2009; 18(1): 115 - 128. [Abstract] [PDF]
|
|
|
|
 |
|
 C. M. Sturgeon, M. J. Duffy, U.-H. Stenman, H. Lilja, N. Brunner, D. W. Chan, R. Babaian, R. C. Bast Jr., B. Dowell, F. J. Esteva, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers Clin. Chem., December 1, 2008; 54(12): e11 - e79. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. D. Evans and L. McCormack Applying Social Marketing in Health Care: Communicating Evidence to Change Consumer Behavior Med Decis Making, September 1, 2008; 28(5): 781 - 792. [Abstract] [PDF]
|
|
|
|
 |
|
 W. Bolland Prostate cancer InnovAiT, September 1, 2008; 1(9): 642 - 650. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U.S. Preventive Services Task Force Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement Ann Intern Med, August 5, 2008; 149(3): 185 - 191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Lin, R. Lipsitz, T. Miller, and S. Janakiraman Benefits and Harms of Prostate-Specific Antigen Screening for Prostate Cancer: An Evidence Update for the U.S. Preventive Services Task Force Ann Intern Med, August 5, 2008; 149(3): 192 - 199. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Williams-Piehota, L. A. McCormack, K. Treiman, and C. M. Bann Health information styles among participants in a prostate cancer screening informed decision-making intervention Health Educ. Res., June 1, 2008; 23(3): 440 - 453. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N J Stephens, N Bharwani, and S D Heenan Prostate cancer staging Imaging, June 1, 2008; 20(2): 112 - 121. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. McFall, J. Ureda, T. L. Byrd, A. Valdes, P. Morales, D. B. Scott, D. Williams, J. Calderon-Mora, M. E. Casillas, and E. C. Y. Chan What is needed for informed decisions about prostate cancer screening: perspectives of African-American and Hispanic men Health Educ. Res., May 9, 2008; (2008) cyn018v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. D. Jacobson Transforming Clinical Practice Guidelines Into Legislative Mandates: Proceed With Abundant Caution JAMA, January 9, 2008; 299(2): 208 - 210. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Labrecque, F. Legare, and M. Cauchon Rebuttal: Should Canadians be offered systematic prostate cancer screening?: NO Can Fam Physician, July 1, 2007; 53(7): 1140 - 1141. [Full Text] [PDF]
|
|
|
|
|
|
M. Labrecque, F. Legare, and M. Cauchon Refutation: Devrait-on offrir aux Canadiens le depistage systematique du cancer de la prostate?: NON Can Fam Physician, July 1, 2007; 53(7): 1142 - 1143. [Full Text] [PDF]
|
|
|
|
|
|
E. A. Singer, D. F. Penson, and G. S. Palapattu PSA Screening and Elderly Men JAMA, March 7, 2007; 297(9): 949 - 949. [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Werny, T. Thompson, M. Saraiya, D. Freedman, B. J. Kottiri, R. R. German, and M. Wener Obesity Is Negatively Associated with Prostate-Specific Antigen in U.S. Men, 2001-2004 Cancer Epidemiol. Biomarkers Prev., January 1, 2007; 16(1): 70 - 76. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J Wilt and I. M Thompson Clinically localised prostate cancer BMJ, November 25, 2006; 333(7578): 1102 - 1106. [Full Text] [PDF]
|
|
|
|
|
|
L. C. Walter, D. Bertenthal, K. Lindquist, and B. R. Konety PSA Screening Among Elderly Men With Limited Life Expectancies. JAMA, November 15, 2006; 296(19): 2336 - 2342. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. McFall US Men Discussing Prostate-Specific Antigen Tests With a Physician. Ann. Fam. Med, September 1, 2006; 4(5): 433 - 436. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Kamangar, G. M. Dores, and W. F. Anderson Patterns of Cancer Incidence, Mortality, and Prevalence Across Five Continents: Defining Priorities to Reduce Cancer Disparities in Different Geographic Regions of the World J. Clin. Oncol., May 10, 2006; 24(14): 2137 - 2150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Saraiya, B. J. Kottiri, S. Leadbetter, D. Blackman, T. Thompson, M. T. McKenna, and F. L. Stallings Total and Percent Free Prostate-Specific Antigen Levels among U.S. Men, 2001-2002 Cancer Epidemiol. Biomarkers Prev., September 1, 2005; 14(9): 2178 - 2182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. C. Sox and C. Mulrow An Editorial Update: Should Benefits of Radical Prostatectomy Affect the Decision To Screen for Early Prostate Cancer? Ann Intern Med, August 2, 2005; 143(3): 232 - 233. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Gattellari, N. Donnelly, N. Taylor, M. Meerkin, G. Hirst, and J. E Ward Does 'peer coaching' increase GP capacity to promote informed decision making about PSA screening? A cluster randomised trial Fam. Pract., June 1, 2005; 22(3): 253 - 265. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. L. Andriole, D. L. Levin, E. D. Crawford, E. P. Gelmann, P. F. Pinsky, D. Chia, B. S. Kramer, D. Reding, T. R. Church, R. L. Grubb, et al. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: Findings From the Initial Screening Round of a Randomized Trial J Natl Cancer Inst, March 16, 2005; 97(6): 433 - 438. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. A. Jaffer and R. Weissleder Molecular Imaging in the Clinical Arena JAMA, February 16, 2005; 293(7): 855 - 862. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Brenner and V. Arndt Long-Term Survival Rates of Patients With Prostate Cancer in the Prostate-Specific Antigen Screening Era: Population-Based Estimates for the Year 2000 by Period Analysis J. Clin. Oncol., January 20, 2005; 23(3): 441 - 447. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Wilding and P. Remington Period Analysis of Prostate Cancer Survival J. Clin. Oncol., January 20, 2005; 23(3): 407 - 409. [Full Text] [PDF]
|
|
|
|
|
|
O. W. Brawley and B. S. Kramer Cancer Screening in Theory and in Practice J. Clin. Oncol., January 10, 2005; 23(2): 293 - 300. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. L. Parnes, I. M. Thompson, and L. G. Ford Prevention of Hormone-Related Cancers: Prostate Cancer J. Clin. Oncol., January 10, 2005; 23(2): 368 - 377. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. C. Y. Chan, S. W. Vernon, C. Ahn, and A. Greisinger Do Men Know That They Have Had a Prostate-Specific Antigen Test? Accuracy of Self-Reports of Testing at 2 Sites Am J Public Health, August 1, 2004; 94(8): 1336 - 1338. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Rychetnik, P. Hawe, E. Waters, A. Barratt, and M. Frommer A glossary for evidence based public health J Epidemiol Community Health, July 1, 2004; 58(7): 538 - 545. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. H. Kuller, A. Thomas, G. Grandits, and J. D. Neaton Elevated Prostate-Specific Antigen Levels Up to 25 Years Prior to Death from Prostate Cancer Cancer Epidemiol. Biomarkers Prev., March 1, 2004; 13(3): 373 - 377. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. N. Lohr Rating the strength of scientific evidence: relevance for quality improvement programs Int. J. Qual. Health Care, February 1, 2004; 16(1): 9 - 18. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. S. Kunkel, B. Meyer, C. Daskalakis, J. Cocroft, K. Jennings-Dozier, and R. E. Myers Behaviors Used by Men to Protect Themselves against Prostate Cancer Cancer Epidemiol. Biomarkers Prev., January 1, 2004; 13(1): 78 - 86. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. T. Robertson Screening for Prostate Cancer Ann Intern Med, September 16, 2003; 139(6): 531 - 532. [Full Text] [PDF]
|
|
|
|
|
|
H. K. Weir, M. J. Thun, B. F. Hankey, L. A. G. Ries, H. L. Howe, P. A. Wingo, A. Jemal, E. Ward, R. N. Anderson, and B. K. Edwards Annual Report to the Nation on the Status of Cancer, 1975-2000, Featuring the Uses of Surveillance Data for Cancer Prevention and Control J Natl Cancer Inst, September 3, 2003; 95(17): 1276 - 1299. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. F. Col The Use of Gene Tests to Detect Hereditary Predisposition to Chronic Disease: Is Cost-Effectiveness Analysis Relevant? Med Decis Making, September 1, 2003; 23(5): 441 - 448. [Abstract] [PDF]
|
|
|
|
|
|
J. M. McWilliams, A. M. Zaslavsky, E. Meara, and J. Z. Ayanian Impact of Medicare Coverage on Basic Clinical Services for Previously Uninsured Adults JAMA, August 13, 2003; 290(6): 757 - 764. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. C. Sorum, J. Shim, G. Chasseigne, S. Bonnin-Scaon, J. Cogneau, and E. Mullet Why do Primary Care Physicians in the United States and France Order Prostate-Specific Antigen Tests for Asymptomatic Patients? Med Decis Making, July 1, 2003; 23(4): 301 - 313. [Abstract] [PDF]
|
|
|
|
 |
|
 T. J Wilt Radical prostatectomy reduced death from prostate cancer but not all cause mortality Evid. Based Med., March 1, 2003; 8(2): 41 - 41. [Full Text] [PDF]
|
|
|
|
 |
|
 Screening for Prostate Cancer: Insufficient Evidence Journal Watch (General), January 10, 2003; 2003(110): 1 - 1. [Full Text]
|
|
|
|
|
|
U.S. Preventive Services Task Force* Screening for Prostate Cancer: Recommendation and Rationale Ann Intern Med, December 3, 2002; 137(11): 915 - 916. [Abstract] [Full Text] [PDF]
|
|
Article
